Now showing items 1-8 of 8
Investigation of PI3K-AKT and EMT-targeted miRNA profiles in palbociclib-treated Panc-1 and MiaPaCa-2 pancreatic cancer cells
The therapeutic strategies of pancreatic cancer (PC) are with the various combination treatment of anti-cancer drugs still in progress. However, the survival rate o f PC is still under 6%. because o f the limited therapeutics ...
Celastrol Modulates Lipid Synthesis via PI3K/Akt/mTOR Signaling Axis to finalize Cell Death Response in Prostate Cancer Cells
FASN is key enzyme during lipid biogenesis is associated with prostate cancer. In this study, we aim to investigate the potential role of celastrol, root extracts of Tripterygium wilfordii on modulation of lipid ...
Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells
(Springer Link, 2018-12)
Diclofenac is a preferential cyclooxygenase 2 inhibitor (COX-2) and member of non-steroidal anti-inflammatory drugs (NSAIDs). Inflammation is one of the main reason of poor prognosis of colon cancer cases; thereby NSAIDs ...
Inhibition of extracellular signal-regulated kinase potentiates the apoptotic and antimetastatic effects of cyclin-dependent kinase inhibitors on metastatic DU145 and PC3 prostate cancer cells
(Wiley Online Library, 2018-10-15)
Purvalanol and roscovitine are specific cyclin‐dependent kinase (CDK) inhibitors,which have antiproliferative and apoptotic effects on various types of cancer.Although, the apoptotic accomplishment of purvalanol and ...
The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells
(Elsevier INC., 2019-12)
Background: Prostate cancer is the most common type of cancer among men. Studies showed that the regular use of nonsteroidal antiinflammatory drugs might reduce disease progression risk for prostate cancer patients with ...
Orlistat as a fatty acid synthase inhibitor blocks cell survival mechanism via activating PTEN, which controls PI3K/AKT/MAPK axis in PC3 prostate cancer cells
(Elsevier Science Bv, Po Box 211, 1000 AE Amsterdam, Netherlands, 2017-08-30)